The herg screening global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
HERG Screening Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The HERG screening market size has grown rapidly in recent years. It will grow from $1.42 billion in 2023 to $1.62 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to increasing drug development activities, regulatory requirements, increasing awareness of cardiac safety, rising incidence of cardiac disorders.
The HERG screening market size is expected to see rapid growth in the next few years. It will grow to $2.60 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expansion of personalized medicine, increasing outsourcing of drug development activities, emerging markets and research, focus on non-cardiac safety assessments. Major trends in the forecast period include advanced in vitro models, integration of genomic and proteomic data, advancements in computational approaches, focus on pediatric drug safety, collaborations for data sharing and standardization.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report
Scope Of HERG Screening Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
HERG Screening Market Overview
Market Drivers –
The rise in the number of patients with heart disorders is expected to propel the growth of the HERG screening market going forward. Heart disorders, also known as cardiovascular disorders or diseases, refer to a range of conditions that affect the heart and blood vessels. These conditions can impact the heart’s ability to function properly and may lead to serious health complications. These disorders arise because of unhealthy lifestyles, an aging population, genetic factors, diabetes, and metabolic syndrome. HERG screening helps to identify potential drug candidates, prevent adverse cardiac events that could induce life-threatening cardiac arrhythmias, particularly torsade de pointes (TdP), and improve patient outcomes. For instance, in May 2023, the Centers for Disease Control and Prevention., a US-based national public health agency, reported that in the US, 1 in 20 adults age 20 and older have cardiovascular diseases, 695,000 people were suffering from cardiovascular diseases in 2021, and 375,476 people died with cardiovascular diseases that same year. Furthermore, in March 2022, according to a report published by the Office for National Statistics, a UK-based government department, 19,440 people died of heart attacks in 2020, and this number increased to 20,061 in 2021. Therefore, the rise in the number of patients with heart disorders is driving the growth of the HERG screening market.
Market Trends –
Major companies operating in the HERG screening market are concentrating on new innovative advanced solutions, such as GLP-certified HERG screening services, to enhance cardiac safety assessments during drug development processes. This service refers to the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the conventional whole-cell patch-clamp technique. It ensures that the screening is conducted in compliance with regulatory guidelines such as ICH S7A and ICH S7B, which are essential for safety pharmacology studies in drug development. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, launched the good laboratory practice (GLP)-certified hERG screening service. This service aims to enhance Metrion’s support for small-molecule therapeutic development and complement the company’s existing cardiac safety service portfolio. Additionally, this service utilizes the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before entering Phase 1 clinical trials in humans, provides regulatory guidance for safety pharmacology studies in drug development, and offers clients high-quality biology services for ion channel targets.
The HERG screening market covered in this report is segmented –
1) By Type: Gene KCNH2, Mutant KCNH2
2) By Ion Channel: Voltage-Gated, Ligand Gated
3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications
Get an inside scoop of the herg screening market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=14391&type=smp
Regional Insights –
North America was the largest region in the HERG screening market in 2023. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B’SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.
Table of Contents
1. Executive Summary
2. HERG Screening Market Characteristics
3. HERG Screening Market Trends And Strategies
4. HERG Screening Market – Macro Economic Scenario
5. Global HERG Screening Market Size and Growth
….
32. Global HERG Screening Market Competitive Benchmarking
33. Global HERG Screening Market Competitive Dashboard
34. Key Mergers And Acquisitions In The HERG Screening Market
35. HERG Screening Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
